Adverts

Open Access Articles- Top Results for JTE-907

JTE-907

</th></tr>
JTE-907
File:JTE-907.png
Systematic (IUPAC) name
N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide
Clinical data
Identifiers
282089-49-0 7pxY
PubChem CID 9867770
ChemSpider 8043461
Chemical data
Formula C24H26N2O6
438.472
 14pxY (what is this?)  (verify)

JTE-907 is a drug used in scientific research that acts as a selective CB2 inverse agonist.[1][2] It has antiinflammatory effects in animal studies,[3] thought to be mediated by an interaction between the CB2 receptor and IgE.[4]

See also

References

  1. ^ Iwamura, H et al. (2001). "In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor". The Journal of Pharmacology and Experimental Therapeutics 296 (2): 420–5. PMID 11160626. 
  2. ^ Raitio, KH et al. (2006). "Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists". Journal of Medical Chemistry 49 (6): 2022–7. PMID 16539390. doi:10.1021/jm050879z. 
  3. ^ Ueda, Y et al. (2005). "Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice". European Journal of Pharmacology 520 (1–3): 164–71. PMID 16153638. doi:10.1016/j.ejphar.2005.08.013. 
  4. ^ Ueda, Y; Miyagawa, N; Wakitani, K (2007). "Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice". Life Sciences 80 (5): 414–9. PMID 17055000. doi:10.1016/j.lfs.2006.09.026. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.